Affinity Asset Advisors LLC Makes New $9.71 Million Investment in Ventyx Biosciences, Inc. $VTYX

Affinity Asset Advisors LLC acquired a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 4,536,182 shares of the company’s stock, valued at approximately $9,707,000. Ventyx Biosciences comprises approximately 1.3% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 25th biggest position. Affinity Asset Advisors LLC owned approximately 0.06% of Ventyx Biosciences as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of VTYX. Pallas Capital Advisors LLC bought a new stake in Ventyx Biosciences in the 2nd quarter worth approximately $38,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Ventyx Biosciences during the second quarter worth approximately $61,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of Ventyx Biosciences by 21.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock worth $62,000 after acquiring an additional 5,174 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Ventyx Biosciences in the 2nd quarter worth approximately $71,000. Finally, Bailard Inc. purchased a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at $88,000. 97.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Oppenheimer raised their price objective on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. HC Wainwright upgraded Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, November 5th. Finally, Wells Fargo & Company raised their price target on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Ventyx Biosciences Trading Up 9.0%

VTYX stock opened at $8.72 on Friday. The firm’s 50-day moving average price is $6.95 and its two-hundred day moving average price is $4.03. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $10.55. The stock has a market capitalization of $622.26 million, a price-to-earnings ratio of -5.81 and a beta of 1.22.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. Equities analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.